COVID-19 vaccine: 'Oxford trials not paused in India', clarifies Serum Institute

clinical trials of Oxford COVID-19 vaccine are continuing in India and have t faced any issue so far, pharmaceutical giant Serum Institue of India (SII) clarified on Wednesday after AstraZeneca paused testing in Britain after a patient volunteering for vaccine trial fell ill.  UK-based company said it is still trying to investigate wher sudden illness of a candidate is a serious side-effect of vaccine.

"We can t comment much on UK trials, but y have been paused for furr review and y hope to restart soon. As far as Indian trials are concerned, it is continuing and we have faced issues at all," SII said in a statement.

RE | WHO Says Safety 'first & Foremost' After AstraZeneca Suspends Vaccine Trials

RE | Australia ‘t Worried’ As AstraZeneca Pauses COVID-19 Vaccine Trial Over Safety Concerns

AstraZeneca pauses its COVID-19 vaccine trial

As per statement issued by AstraZeneca on September 8, Tuesday, company anunced that it's standard review process has triggered a pause to vaccination to allow review of safety data. However, company has t shared any more information about possible side-effect rar than just calling it 'a potentially unexplained illness'. Right after news of pause in COVID-19 vaccine trial of AstraZeneca came out, its U.S tre shares fell by 6 per cent immediately. spokesperson of AstraZeneca has confirmed pause in COVID-19 vaccination cover studies in U.S and or countries. 

SII h initiated phase two and three clinical trials to evaluate safety and immune response of Oxford University coronavirus vaccine candidate on healthy Indian ults after pharma company got approval from Drugs Controller General of India (DCGI) last month. In India, vaccine would be manufactured by company.

According to Clinical Trial Registry India, scientific title of study says that phase 2/3 clinical trial will be an observer-blind, randomised, controlled study to determine safety and immugenicity of Covishield (COVID-19 vaccine) in healthy Indian ults. A total of 1,600 eligible participants of more than or equal to 18 years of will be enrolled in study, which will be conducted on 17 sites in India.

(With ANI inputs)

RE | Phase 3 Clinical Trials Of Sputnik V Coronavirus Vaccine To Start Today

RE | AstraZeneca Puts Its COVID-19 Vaccine Trial On Hold After Patient In UK Falls Ill